This Phase II TEC Validation Project™ via the Technology Evaluation Consortium™ and researchers at Northeastern University is validating nanoparticle technology that could forever change the delivery of drugs.
BOSTON, MA (PRWEB) January 31, 2016
The Technology Evaluation Consortium™ (TEC), managed by One Million Solutions in Health™, recently completed a successful Phase I TEC Validation Project™. In this Phase I project, it was shown that the patented nanoparticle technology process developed by researchers at Northeastern University could incorporate compounds, such as poorly water-soluble drugs, into an assembly of fully functional nanoparticle structures. Based on this success, the TEC and the Center for High-rate Nanomanufacturing (CHN) have announced their intention to begin a Phase II TEC Validation Project™.
Dr. Ahmed Busnaina, the Director of the CHN, and a Distinguished Professor and holder of the WL Smith Chair at Northeastern University in Boston, is the lead investigator responsible for developing the nanoparticle technology. This new manufacturing process produces nanoparticle structures with a unique ability to pass through normal tissue boundaries. The research team has found that nano-sized particles can be fabricated into distinct shapes, such as nanopillars, with controlled size and shape that could potentially have high tissue permeability. This process could have far-reaching impacts, including important applications within the pharmaceutical industry.
The goals of a Phase II Validation Project will be three-fold. Firstly, researchers wish to increase the number of drug-loaded nanorods for in vitro characterization. Success in this area will demonstrate the feasibility of fabricating drug-loaded nanorods with sufficient drug dosage to perform in vitro characterization for the next two goals. The second goal is to evaluate the in vitro permeability and cytotoxicity of drug-loaded micellar nanorods in cell lines. The final goal is to evaluate in vivo permeability and cytotoxicity of drug-loaded micellar nanorods in animal studies.
“We are excited to be advancing to the next step with Northeastern University,” explained Dawn Van Dam, President and CEO of One Million Solutions in Health. “The team at CHN have developed highly relevant and unique nanoparticle technology that will be extraordinarily helpful for the pharmaceutical industry, once the technology is validated by the Technology Evaluation Consortium.”
The consortium will bring together a number of industry leaders from pharmaceutical companies to evaluate and further qualify the CHN’s patented nanoparticle technology process. Consortium members and pharma experts affiliated with the university will share ideas and solutions with the hopes of creating a likely path of adoption for Northeastern University’s nanoparticle technology.
We are working with leading companies like AbbVie, Allergan, Amgen, Janssen (Johnson & Johnson) and Novartis – and expect to have the results from this nanoparticle technology evaluation to be applicable to dozens of pharmaceutical and other medicinal companies that struggle with formulating non-soluble compounds (intravenous) so that the drugs can be swallowed, instead.
In the end, this will allow more patients to be able to access important medications, thereby enhancing the success of medical care in many diseases.
ABOUT ONE MILLION SOLUTIONS IN HEALTH
The goal of One Million Solutions in Health™ is to shape health care by sharing solutions and, importantly, to accelerate the discovery, development and delivery ... of innovative cures, treatments and preventative measures for patients around the world.
In this next year, we will be reviewing 1000's of new solutions and new scientific discoveries. By engaging scientists, entrepreneurs, investors, innovators, industry experts, health care professionals, and patients across various disciplines, and from around the world, we can utilize the power of the internet to disrupt things in a positive and transformative way to accelerate the movement of new solutions and scientific discoveries from the scientist to the patient.
We are on our way towards accelerating high-potential innovations, catalyzing investment and increasing awareness of, and support for, transformative ideas to improve health and save lives. By facilitating efforts to ensure organizations can Connect, Learn + Share, Innovate and Collaborate, our vision is to improve health care delivery, accelerate life sciences research and share patient and consumer-focused ideas and solutions.
As a not-for-profit, we welcome your participation and are thrilled to have you be a part of this transformative journey!
ABOUT THE TECHNOLOGY EVALUATION CONSORTIUM
The Technology Evaluation Consortium™ from One Million Solutions in Health™ is dedicated to improving and accelerating life sciences R&D and health care outcomes. The Technology Evaluation Consortium brings together life sciences and/or health care companies and industry vendors or scientists, and other relevant partners (e.g., government and Universities), to evaluate and validate technologies or services in a collaborative environment.
The model empowers technology providers/scientists and industry end-users to collectively assess a number of solutions in a cost-effective manner, producing a depth and breadth of results that no company can achieve alone. Our mission is to triage and streamline new technology consideration for the industry and to be the place for the industry to conduct their evaluations and validations.
ABOUT NORTHEASTERN UNIVERSITY
The Center for High-rate Nanomanufacturing (CHN) at Northeastern University in Boston is focused on developing tools and processes that will make it possible for businesses to quickly and efficiently manufacture products that have unique characteristics due to their size and shape. The CHN’s work on advancing our capacity to make high-rate, value-added products using nanoparticles and specialized processes is one of many initiatives that are making the university a leader in nanotechnology.
Northeastern’s advances in affective science, drug discovery and delivery, personal health informatics, and sensors are characterized by global collaborations with industry, government, and other academic institutions. Its leadership in nanotechnology and data science provides a growing technological foundation for new discoveries in these and other areas of interdisciplinary research. http://www.nanomanufacturing.us.
Dawn Van Dam
President and CEO